Clinical Trial Update: Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

An ongoing Phase 1/2 study investigates systemic VSV-IFNβ-NIS in combination with checkpoint inhibitors for select solid tumors. The trial is active but not cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma
• Solid Tumor

Drugs mentioned

• VSV-IFNβ-NIS (vesicular stomatitis virus expressing interferon-beta and NIS)

Snippet

Sponsor: Vyriad, Inc. | Conditions: Solid Tumor, Non Small Cell Lung Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING